Okyo Pharma Ltd
SEC CIK 1849296 · OKYO · last insider filing 2026-06-17
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Cerrone Gabriele M | Director · Non-Executive Chairman | filed 2022 - 2026 |
| Brancaccio John P | Director | filed 2022 - 2026 |
| Simon Willy Jules | Director | filed 2022 - 2026 |
| Denoyer Bernard | Director | filed 2022 - 2026 |
| Dempsey Robert John | Director · CHIEF EXECUTIVE OFFICER | filed 2026 - 2026 |
| Jacob Gary S | Director · Chief Executive Officer | filed 2022 - 2026 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Mantelli Flavio | CHIEF MEDICAL OFFICER | filed 2026 - 2026 |
| Shah Keeren Rameshchandra | Chief Financial Officer | filed 2026 - 2026 |
| Shah Keeren | Chief Financial Officer | filed 2022 - 2022 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.